文献速递脑血管病认知障碍与痴呆

脑脊液生物标志物评估可能脑淀粉样血管病的疾病严重程度

Evaluation of Disease Severity Using CSF Biomarkers in Patients With Probable Cerebral Amyloid Angiopathy.
PubMed 文献 · Neurology · 2026-09-03

该回顾性多中心队列研究纳入102例按Boston标准v2.0诊断的可能脑淀粉样血管病(CAA)患者,分析脑脊液Aβ42、Aβ40、总tau和p-tau181与MRI严重程度标志物的关联。结果显示较低的脑脊液Aβ40和Aβ42水平与更大的皮质表面铁沉积负担和更高的Fazekas评分显著相关,但与脑微出血计数无关,tau物种与MRI标志物无显著关联。

要点

  • 低脑脊液Aβ40和Aβ42与可能CAA患者更高的Fazekas评分和更大的皮质表面铁沉积负担独立相关。
  • 脑脊液Aβ水平与脑微出血计数无显著关联,tau物种与MRI标志物亦无显著关联。
  • 脑脊液Aβ水平可能反映血管淀粉样蛋白负担而非下游神经变性。

核心结论

  • 在可能CAA患者中,较低的脑脊液Aβ40和Aβ42水平与已建立的MRI疾病严重程度标志物相关,且独立于临床表现和伴随的阿尔茨海默样profile。

研究设计与样本

  • 回顾性多中心队列研究,纳入2个三级中心2014至2023年连续诊断的可能CAA(Boston标准v2.0)且接受腰椎穿刺的患者,共102例,平均年龄72.0±7.5岁,65%男性。

主要发现

  • 较低脑脊液Aβ40与更大cSS负担相关(标准化β -0.49,95%CI -0.8至-0.17,p=0.002),较低Aβ42亦相关(β -0.42,95%CI -0.73至-0.11,p=0.007)。
  • 较低脑脊液Aβ40与更高Fazekas评分相关(β -0.18,95%CI -0.33至-0.03,p=0.02),较低Aβ42亦相关(β -0.23,95%CI -0.38至-0.08,p=0.002)。
  • 脑脊液Aβ40和Aβ42与CMB计数无显著关联,tau物种与MRI标志物无显著关联。
  • 按脑脊液Aβ42/Aβ40定义的阿尔茨海默样profile分层后关联仍显著。

关键数值与推荐

  • CAA诊断依据Boston标准v2.0。
  • 脑脊液Aβ42、Aβ40、总tau和p-tau181采用标准化免疫测定法测量。

临床怎么用

  • 脑脊液Aβ40和Aβ42水平或可作为反映可能CAA血管淀粉样蛋白负担的辅助指标,用于评估疾病严重程度。
  • 脑脊液Aβ水平与MRI严重程度标志物的关联独立于临床表现和阿尔茨海默样profile,解读时需综合考虑。

局限性

  • 回顾性研究设计。
  • 样本量有限(102例)。
  • 需要前瞻性纵向研究确定脑脊液Aβ水平的预后价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cerebral amyloid angiopathy (CAA) is currently diagnosed using MRI-based Boston criteria. However, imaging markers represent downstream consequences of vascular injury and may not fully reflect disease severity. CSF biomarkers, particularly β-amyloid 1-42 (Aβ42) and β-amyloid 1-40 (Aβ40), may provide a more direct measure of vascular amyloid burden. We investigated the association between CSF biomarkers and hemorrhagic and nonhemorrhagic MRI markers of disease severity in probable CAA. METHODS: We conducted a retrospective multicenter cohort study including consecutive patients diagnosed with probable CAA according to Boston criteria v2.0 at 2 tertiary centers (2014-2023) who underwent lumbar puncture (LP) as part of clinical evaluation. CSF Aβ42, Aβ40, total tau, and phosphorylated-tau 181 (p-tau181) were measured using standardized immunoassays. MRI markers included lobar cerebral microbleeds (CMBs), cortical superficial siderosis (cSS), white matter hyperintensity burden, Fazekas score, and enlarged perivascular spaces in the centrum semiovale. Multivariable linear regression models were adjusted for age, sex, MRI sequence type, and delay between onset and LP. False discovery rate correction was applied for multiple testing. We also used principal component analysis to explore associations between MRI and CSF biomarkers. RESULTS: A total of 102 patients were included (mean age at LP 72.0 ± 7.5 years; 65% male). Initial presentations were cognitive impairment in 53%, intracerebral hemorrhage in 34%, and transient focal neurologic episodes in 13%. Lower CSF Aβ40 and Aβ42 levels were significantly associated with greater cSS burden (standardized β -0.49 [95% CI -0.8 to -0.17], p = 0.002 and -0.42 [-0.73 to -0.11], p = 0.007, respectively) and higher Fazekas score (β -0.18 [-0.33 to -0.03], p = 0.02 and -0.23 [-0.38 to -0.08], p = 0.002) but not with CMB count. No significant association was found between tau species and MRI markers. Associations remained significant after stratification by CSF Aβ42/Aβ40-defined Alzheimer-like profile. DISCUSSION: In probable CAA, lower CSF Aβ40 and Aβ42 levels are associated with established MRI markers of disease severity, independently of clinical presentation and concomitant Alzheimer-like profile. These findings suggest that CSF Aβ levels may reflect vascular amyloid burden rather than downstream neurodegeneration. Prospective longitudinal studies are needed to determine their prognostic value.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Beaufort Q, Charbonnier C, Ruellan P, et al. Evaluation of Disease Severity Using CSF Biomarkers in Patients With Probable Cerebral Amyloid Angiopathy. Neurology. 2026. PMID: 42691466. doi:10.1212/WNL.0000000000218458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。